Pfizer documents: Cumulative Analysis of Post-authorization Adverse Event Reports

Released April 1, 2022

Although the report contains a list of adverse events spanning 9 pages (Appendix 1), Pfizer still concludes that these findings of their “signal detection analyses are consistent with the known safety profile” of their product BNT162b2 and the “cumulative post-marketing experience confirms a favourable benefit-risk balance”.

You might also be interested in

Latest articles

Stephanie Seneff, Greg Nigh, Anthony M. Kyriakopoulos, Peter A. McCullough Innate immune...
Geert Vanden Bossche When a deep understanding of immunology, virology, vaccinology, evolutionary...
Stefan Lanka The present notion of a virus is based on the...

Your donation helps us
stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.

Stay up to date

Sign up to our newsletter to get the latest health-related news and events delivered straight to your inbox.

Become a CHA member

Become an active value-added member and trusted provider of medical and healthcare information and education by joining the CHA Membership Program.

Your donation helps us stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.